t lymphocytes
Cell therapyexperimental
T cells are an important part of the immune system and play a central role in the adaptive immune response. T cells can be distinguished from other lymphocytes by the presence of a T-cell receptor (TCR) on their cell surface. — Wikipedia
Clinical trial activity
28 trials · 32 clinical orgs · 0 marketing orgs
Phase 1
22
Phase 2
13
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2000 (NCT00586547)
Timeline
Indications
Studied for
- Anemia, Aplastic · Phase 2
- Anemia, Refractory · Phase 2
- Antigens, CD19 · Phase 1
- Bone Marrow Cells · Phase 1
- Brain Neoplasms · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Carcinoma, Squamous Cell · Phase 1
- Colorectal Neoplasms · Phase 1
- Cytomegalovirus Infections · Phase 1/Phase 2
- Esophageal Neoplasms · Phase 1
- Fanconi Anemia · Phase 1
- Glioblastoma · Phase 1/Phase 2
- Glioma · Phase 1/Phase 2
- Gliosarcoma · Phase 1/Phase 2
- Graft vs Host Disease · Phase 2
- Head and Neck Neoplasms · Phase 1
- Hematologic Neoplasms · Phase 1/Phase 2
- Hematopoietic Stem Cell Transplantation · Phase 1
- HIV Infections · Phase 1
- Hodgkin Disease · Phase 2
- Immune Tolerance · Phase 1
- Kidney Failure, Chronic · Phase 1
- Leukemia · Phase 2
- Leukemia, Biphenotypic, Acute · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1/Phase 2
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 1/Phase 2
- Leukemia, Myeloid, Acute · Phase 2
- Leukemia, Myeloid, Chronic-Phase · Phase 1/Phase 2
- Leukemia, Myelomonocytic, Chronic · Phase 2
- Lymphoma · Phase 2
- Lymphoma, Non-Hodgkin · Phase 2
- Melanoma · Phase 2
- Multiple Myeloma · Phase 2
- Myelodysplastic Syndromes · Phase 2
- Myeloproliferative Disorders · Phase 2
- Neoplasm Metastasis · Phase 1
- Neoplasm, Residual · Phase 1
- Neoplasms · Phase 2
- Organ Transplantation · Phase 1
- Pancreatic Neoplasms · Phase 1
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 1/Phase 2
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
- Renal Insufficiency, Chronic · Phase 1
- Sezary Syndrome · Phase 1
- Small Cell Lung Carcinoma · Phase 2
- Stomach Neoplasms · Phase 1
- Thrombocytopenia · Phase 2
Mechanism of action
- Unspecified targetImmunity, passive
immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaT cell ↗
Also known as
- donor t-cells
- t-cell
- t cells
- t-cells
- t-cells rituximab + il-2
- t-lymphocytes
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06990087 | Phase 2 | Nov 30, 2025 | Gottfried Wilhelm Leibniz Universität Hannover |
| NCT05806749 | Phase 1 | Jul 7, 2023 | University of California, Los Angeles |
| NCT04678401 | Phase 1 | Jan 12, 2021 | Harvard University |
| NCT03263767 | Phase 2 | Jan 31, 2018 | University of Nantes |
| NCT02757391 | Phase 1 | Aug 1, 2017 | Merck, University of Texas at Houston |
| NCT02956551 | Phase 1 | Nov 1, 2016 | Sichuan University |
| NCT02849886 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2016 | Bellicum Pharmaceuticals, Etablissement Français du Sang, University of Franche-Comté |
| NCT02661282 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2016 | Gateway for Cancer Research, Marnie Rose Foundation, University of Texas at Houston |
| NCT02529813 | Phase 1 | Dec 1, 2015 | Intrexon, University of Texas at Houston, Ziopharm |
| NCT02548468 | Phase 1 | Nov 20, 2015 | Thomas Jefferson University |
| NCT02566304 | Phase 2 | Nov 1, 2015 | Thomas Jefferson University |
| NCT01740557 | Phase 1/Phase 2 (Phase 2) | Jan 28, 2015 | Key Biologics, LLC, National Cancer Institute (NCI), National Institutes of Health (NIH), Prometheus Inc., University of Texas at Houston |
| NCT02315118 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2014 | National University of Singapore, Singapore General Hospital |
| NCT01955460 | Phase 1 | Oct 1, 2014 | State of Texas, University of Texas at Houston |
| NCT02274506 | Phase 1 | Jul 1, 2014 | University of Texas at Houston |
| NCT01946373 | Phase 1 | Oct 1, 2013 | Karolinska Institute |
| NCT01653717 | Phase 1 | Jun 1, 2013 | University of Texas at Houston |
| NCT02843321 | Phase 1 | Aug 1, 2012 | University of Sydney |
| NCT01518153 | Phase 2 | Feb 1, 2012 | University of Texas at Houston |
| NCT01660607 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2011 | National Institutes of Health (NIH), Stanford University |
Showing 20 of 28 trials
Page 1 / 2
Organizations
Research & Development (32)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Texas at Houston | Academic/Hospital | 9 | 9 | 2 | 2006 |
| Baylor University | Academic/Hospital | 2 | 2 | 1 | 2000 |
| Key Biologics, LLC | For profit | 2 | 0 | 1 | 2006 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 1 | 2006 |
| National Institutes of Health (NIH) | Government | 2 | 0 | 1 | 2011 |
| Prometheus Inc. | For profit | 2 | 0 | 1 | 2006 |
| Stanford University | Academic/Hospital | 2 | 2 | 1 | 2009 |
| The University of Texas, Dallas | Academic/Hospital | 2 | 0 | 1 | 2000 |
| Thomas Jefferson University | Academic/Hospital | 2 | 2 | 2 | 2015 |
| University of Copenhagen | Academic/Hospital | 2 | 2 | 2 | 2009 |
| Bellicum Pharmaceuticals | For profit | 1 | 0 | 1 | 2016 |
| Doris Duke Charitable Foundation | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Etablissement Français du Sang | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Gateway for Cancer Research | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Gottfried Wilhelm Leibniz Universität Hannover | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Intrexon | For profit | 1 | 0 | 1 | 2015 |
| Karolinska Institute | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Marnie Rose Foundation | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Merck | For profit | 1 | 0 | 1 | 2017 |
32 organizations
Page 1 / 2